Autoimmune Diseases: When the Immune System Attacks the Body

Over 80 autoimmune diseases affect 24 million Americans. Learn why the immune system attacks healthy tissue, how diagnosis works, and how conditions are treated.

The InfoNexus Editorial TeamMay 15, 20269 min read

When Defense Becomes Attack

The human immune system is built to distinguish self from non-self — to identify and destroy bacteria, viruses, parasites, and abnormal cells while leaving healthy tissue untouched. In approximately 24 million Americans, this discrimination fails. The immune system targets the body's own proteins, tissues, and organs as if they were pathogens. The result is autoimmune disease — a category encompassing more than 80 distinct conditions, from rheumatoid arthritis and lupus to multiple sclerosis and type 1 diabetes.

Collectively, autoimmune diseases affect roughly 5 to 8 percent of the U.S. population. They are the third most common category of illness in the country after heart disease and cancer, and they disproportionately affect women — who account for approximately 78 percent of those diagnosed.

The Immunological Breakdown: Central and Peripheral Tolerance

The immune system normally learns to tolerate the body's own tissues through two mechanisms:

Central Tolerance

In the thymus (for T cells) and bone marrow (for B cells), developing immune cells that react too strongly to self-antigens are eliminated — a process called clonal deletion. T cells that would attack self-proteins are destroyed before they can enter circulation. This process is not perfect: some autoreactive cells escape.

Peripheral Tolerance

Autoreactive cells that escape central deletion are kept in check in the periphery by regulatory T cells (Tregs), anergy (functional unresponsiveness), and activation-induced cell death. When peripheral tolerance breaks down, autoreactive lymphocytes become activated and begin attacking self-tissues.

The FOXP3 gene encodes a transcription factor essential for Treg development. Mutations in FOXP3 cause IPEX syndrome — a severe, early-onset multi-organ autoimmune disease that illustrates what happens when regulatory mechanisms fail entirely.

Why Autoimmunity Develops: Contributing Factors

  • Genetic predisposition: HLA (human leukocyte antigen) genes are the strongest genetic risk factors. Specific HLA alleles are associated with lupus, rheumatoid arthritis, type 1 diabetes, and celiac disease. Concordance rates in identical twins range from 25 to 50 percent for most autoimmune diseases — indicating strong but incomplete genetic determination.
  • Sex hormones: Estrogen enhances immune responses and is associated with higher autoimmune disease prevalence in women. Many conditions flare during pregnancy or in the postpartum period.
  • Infections as triggers: Molecular mimicry — structural similarity between pathogen antigens and self-proteins — may activate autoreactive immune cells. Epstein-Barr virus (EBV) has been strongly linked to multiple sclerosis, lupus, and rheumatoid arthritis.
  • Gut microbiome: Dysbiosis (altered microbial composition) has been associated with multiple autoimmune diseases. The microbiome influences immune development and peripheral tolerance mechanisms.
  • Vitamin D deficiency: Low vitamin D levels correlate with higher rates of multiple sclerosis and type 1 diabetes, though causality is debated.

Common Autoimmune Diseases and Their Targets

DiseasePrimary TargetKey Autoantibodies/MechanismsPrevalence
Rheumatoid arthritisSynovial jointsAnti-CCP, rheumatoid factor~1% of adults
Systemic lupus erythematosusMultiple organs (skin, kidneys, joints, brain)Anti-dsDNA, anti-Smith~150 per 100,000
Type 1 diabetesPancreatic beta cellsAnti-GAD, anti-islet cell~8.4 million (U.S.)
Multiple sclerosisCNS myelin sheathT cell-mediated myelin attack~1 million (U.S.)
Hashimoto's thyroiditisThyroid glandAnti-TPO, anti-thyroglobulin~5% of adults
Celiac diseaseSmall intestinal villiAnti-tTG, anti-endomysial~1% globally
PsoriasisSkin keratinocytesIL-17 and IL-23 axis~2–3% of adults

The Diagnostic Challenge

Autoimmune diseases are notoriously difficult to diagnose. The average patient with a systemic autoimmune disease waits nearly 4 years and sees four or more physicians before receiving a correct diagnosis, according to the American Autoimmune Related Diseases Association. Symptoms are often nonspecific — fatigue, joint pain, skin rashes, fever — and overlap across conditions.

Diagnostic tools include:

  • Autoantibody panels (ANA screen, anti-dsDNA, anti-CCP, ANCA)
  • Inflammatory markers (ESR, CRP, ferritin)
  • Complement levels (C3, C4 — often low in active lupus)
  • Complete blood count (cytopenias are common in lupus and other systemic diseases)
  • Organ-specific tests (thyroid function, kidney function, liver enzymes)
  • Tissue biopsy (kidney, skin, nerve, or muscle)

Treatment Strategies

No cure exists for most autoimmune diseases. Treatment aims to suppress aberrant immune activity, reduce inflammation, prevent organ damage, and achieve remission.

Treatment ClassExamplesMechanism
CorticosteroidsPrednisone, methylprednisoloneBroad anti-inflammatory; suppresses cytokine production
Disease-modifying drugs (DMARDs)Methotrexate, hydroxychloroquine, azathioprineReduce immune activity and disease progression
Biologic agentsTNF inhibitors (adalimumab), IL-6 inhibitors (tocilizumab), B-cell depleters (rituximab)Target specific cytokines or immune cell populations
JAK inhibitorsTofacitinib, baricitinib, upadacitinibBlock intracellular signaling pathways driving inflammation
Intravenous immunoglobulin (IVIG)Pooled human IgGModulates immune function via multiple mechanisms

Remission, Flares, and Long-Term Management

Most autoimmune diseases follow a relapsing-remitting or chronic progressive course. Triggers for flares include infections, UV light exposure, stress, hormonal changes, and medication non-adherence. Monitoring disease activity requires regular laboratory and clinical assessments tailored to each condition — kidney function monitoring in lupus nephritis, joint imaging in rheumatoid arthritis, MRI surveillance in multiple sclerosis.

Research into immune tolerance restoration — including regulatory T cell therapies, antigen-specific tolerance induction, and microbiome modification — represents a frontier that may eventually offer disease modification rather than symptom suppression.

This article is for informational purposes only. Consult a qualified healthcare professional before making any health decisions.

autoimmuneimmune systemchronic conditions

Related Articles